GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (LTS:0MGB) » Definitions » Cyclically Adjusted Revenue per Share

Genmab A/S (LTS:0MGB) Cyclically Adjusted Revenue per Share : kr112.50 (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Genmab A/S Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Genmab A/S's adjusted revenue per share for the three months ended in Mar. 2024 was kr63.099. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr112.50 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Genmab A/S's average Cyclically Adjusted Revenue Growth Rate was 30.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 35.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 38.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Genmab A/S was 42.30% per year. The lowest was 32.80% per year. And the median was 36.70% per year.

As of today (2024-06-06), Genmab A/S's current stock price is kr1949.00. Genmab A/S's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was kr112.50. Genmab A/S's Cyclically Adjusted PS Ratio of today is 17.32.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Genmab A/S was 72.33. The lowest was 17.08. And the median was 50.79.


Genmab A/S Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Genmab A/S's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab A/S Cyclically Adjusted Revenue per Share Chart

Genmab A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.31 42.38 55.56 82.27 104.89

Genmab A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 86.56 92.38 100.07 104.89 112.50

Competitive Comparison of Genmab A/S's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Genmab A/S's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab A/S's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab A/S's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Genmab A/S's Cyclically Adjusted PS Ratio falls into.



Genmab A/S Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Genmab A/S's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=63.099/118.4000*118.4000
=63.099

Current CPI (Mar. 2024) = 118.4000.

Genmab A/S Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 2.040 99.700 2.423
201409 4.720 99.700 5.605
201412 3.734 99.400 4.448
201503 1.789 100.200 2.114
201506 2.847 100.300 3.361
201509 4.555 100.200 5.382
201512 9.668 99.800 11.470
201603 2.805 100.200 3.314
201606 5.721 100.600 6.733
201609 5.905 100.200 6.978
201612 14.986 100.300 17.690
201703 4.050 101.200 4.738
201706 12.458 101.200 14.575
201709 5.124 101.800 5.960
201712 16.348 101.300 19.108
201803 10.975 101.700 12.777
201806 8.236 102.300 9.532
201809 9.655 102.400 11.164
201812 19.901 102.100 23.078
201903 9.604 102.900 11.051
201906 12.293 102.900 14.145
201909 16.036 102.900 18.452
201912 45.008 102.900 51.788
202003 13.562 103.300 15.544
202006 82.862 103.200 95.066
202009 26.153 103.500 29.918
202012 30.932 103.400 35.419
202103 23.960 104.300 27.199
202106 29.902 105.000 33.718
202109 34.961 105.800 39.125
202112 38.614 106.600 42.888
202203 32.127 109.900 34.612
202206 47.924 113.600 49.949
202209 62.001 116.400 63.066
202212 77.751 115.900 79.428
202303 43.050 117.300 43.454
202306 63.759 116.400 64.855
202309 72.017 117.400 72.630
202312 70.839 116.700 71.871
202403 63.099 118.400 63.099

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Genmab A/S  (LTS:0MGB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Genmab A/S's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1949.00/112.5
=17.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Genmab A/S was 72.33. The lowest was 17.08. And the median was 50.79.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Genmab A/S Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Genmab A/S's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab A/S (LTS:0MGB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (LTS:0MGB) » Definitions » Cyclically Adjusted Revenue per Share
Address
Kalvebod Brygge 43, Copenhagen, DNK, 1560
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab A/S (LTS:0MGB) Headlines

No Headlines